$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

$enta Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000119312515284854 Filed on August 10, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$14.42M	$11.60M	$42.05M
YoY Change	446.68%	-72.42%	2450.09%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.690M	$3.640M	$2.600M
YoY Change	33.7%	40.0%	45.25%
% of Gross Profit
Research & Development	$7.050M	$6.253M	$4.553M
YoY Change	35.58%	37.34%	12.73%
% of Gross Profit
Depreciation & Amortization	$200.0K	$170.0K	$90.00K
YoY Change	81.82%	88.89%	50.0%
% of Gross Profit
Operating Expenses	$10.74M	$6.253M	$4.553M
YoY Change	34.92%	37.34%	12.73%
Operating Profit		$1.703M	$34.90M
YoY Change		-95.12%	-935.21%
Interest Expense	$510.0K	$2.000K	$5.000K
YoY Change	112.5%	-60.0%	-28.57%
% of Operating Profit		0.12%	0.01%
Other Income/Expense, Net	$509.0K	$287.0K	$36.00K
YoY Change	115.68%	697.22%	-10.0%
Pretax Income	$4.180M	$1.990M	$34.93M
YoY Change	-182.12%	-94.3%	-944.15%
Income Tax	$1.629M	$428.0K	$15.12M
% Of Pretax Income	38.97%	21.51%	43.29%
Net Earnings	$5.812M	$2.418M	$50.05M
YoY Change	-215.27%	-95.17%	-1309.59%
Net Earnings / Revenue	40.32%	20.85%	119.03%
Basic Earnings Per Share	$0.30	$0.13	$2.70
Diluted Earnings Per Share	$0.29	$0.13	$2.61
COMMON SHARES
Basic Shares Outstanding	18.71M shares	18.70M shares	18.53M shares
Diluted Shares Outstanding		19.28M shares	19.20M shares

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$145.2M	$154.3M	$95.90M
YoY Change	59.91%	60.9%	1.48%
Cash & Equivalents	$21.73M	$19.84M	$26.37M
Short-Term Investments	$123.5M	$134.4M	$69.50M
Other Short-Term Assets	$9.700M	$5.300M	$13.20M
YoY Change	-23.62%	-59.85%	780.0%
Inventory
Prepaid Expenses
Receivables	$15.29M	$11.72M	$399.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$170.6M	$172.6M	$111.7M
YoY Change	58.04%	54.59%	14.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.886M	$2.582M	$1.551M
YoY Change	226.46%	66.47%	34.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$64.20M	$57.70M	$41.70M
YoY Change	56.59%	38.37%	106.44%
Other Assets	$5.200M	$4.900M	$4.600M
YoY Change	13.04%	6.52%	1050.0%
Total Long-Term Assets	$75.37M	$65.13M	$47.84M
YoY Change	58.88%	36.16%	119.38%
TOTAL ASSETS
Total Short-Term Assets	$170.6M	$172.6M	$111.7M
Total Long-Term Assets	$75.37M	$65.13M	$47.84M
Total Assets	$246.0M	$237.8M	$159.5M
YoY Change	58.29%	49.06%	33.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.543M	$1.614M	$1.284M
YoY Change	-17.66%	25.7%	39.87%
Accrued Expenses	$3.962M	$3.469M	$2.984M
YoY Change	37.95%	16.25%	47.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K
YoY Change
Total Short-Term Liabilities	$6.704M	$7.312M	$4.268M
YoY Change	41.26%	71.32%	45.12%
LONG-TERM LIABILITIES
Long-Term Debt	$700.0K	$400.0K	$200.0K
YoY Change	250.0%	100.0%
Other Long-Term Liabilities	$1.713M	$538.0K	$405.0K
YoY Change	648.03%	32.84%	-24.3%
Total Long-Term Liabilities	$1.713M	$538.0K	$405.0K
YoY Change	648.03%	32.84%	-24.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.704M	$7.312M	$4.268M
Total Long-Term Liabilities	$1.713M	$538.0K	$405.0K
Total Liabilities	$9.856M	$9.492M	$6.561M
YoY Change	45.78%	44.67%	24.73%
SHAREHOLDERS EQUITY
Retained Earnings	$5.980M	$168.0K	-$67.97M
YoY Change	-108.19%	-100.25%	-34.01%
Common Stock	$230.1M	$228.2M	$188.0K
YoY Change	3.78%	121277.66%	4.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$2.000K	$2.000K
YoY Change		0.0%	0.0%
Treasury Stock Shares	0.000 shares	208.8K shares	208.8K shares
Shareholders Equity	$236.2M	$228.3M	$153.0M
YoY Change
Total Liabilities & Shareholders Equity	$246.0M	$237.8M	$159.5M
YoY Change	58.29%	49.06%	33.29%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	$5.812M	$2.418M	$50.05M
YoY Change	-215.27%	-95.17%	-1309.59%
Depreciation, Depletion And Amortization	$200.0K	$170.0K	$90.00K
YoY Change	81.82%	88.89%	50.0%
Cash From Operating Activities	-$2.380M	-$14.20M	$35.11M
YoY Change	-51.72%	-140.44%	-693.07%
INVESTING ACTIVITIES
Capital Expenditures	-$1.580M	-$400.0K	-$370.0K
YoY Change	222.45%	8.11%	640.0%
Acquisitions
YoY Change
Other Investing Activities	$5.680M	$8.570M	-$26.93M
YoY Change	-41.44%	-131.82%	-44.08%
Cash From Investing Activities	$4.090M	$8.180M	-$27.32M
YoY Change	-55.64%	-129.94%	-43.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	160.0K	120.0K	470.0K
YoY Change	300.0%	-74.47%	-132.64%
NET CHANGE
Cash From Operating Activities	-2.380M	-14.20M	35.11M
Cash From Investing Activities	4.090M	8.180M	-27.32M
Cash From Financing Activities	160.0K	120.0K	470.0K
Net Change In Cash	1.870M	-5.900M	8.260M
YoY Change	-56.81%	-171.43%	-114.86%
FREE CASH FLOW
Cash From Operating Activities	-$2.380M	-$14.20M	$35.11M
Capital Expenditures	-$1.580M	-$400.0K	-$370.0K
Free Cash Flow	-$800.0K	-$13.80M	$35.48M
YoY Change	-81.98%	-138.9%	-704.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18713976	shares
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8859000
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26374000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1389437	shares
CY2014Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	208816	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.39
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18594574	shares
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18803390	shares
CY2014Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	221580000
CY2014Q3	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	153000
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	312000
CY2014Q3	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	76000
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1275000
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	148654000
CY2014Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	229000
CY2014Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	116000
CY2014Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	436000
CY2014Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2014Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000
CY2014Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1786000
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1874000
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2872000
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73012000
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q3	us-gaap	Assets Current AssetsCurrent	107975000
CY2014Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	60065000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1749947	shares
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	208816	shares
CY2014Q3	us-gaap	Liabilities Liabilities	6761000
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155415000
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	188000
CY2014Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	436000
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4746000
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000
CY2014Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1584000
CY2014Q3	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	4198000
CY2014Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	101068000
CY2014Q3	us-gaap	Assets Assets	155415000
CY2014Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	114000
CY2014Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	131307000
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1724000
CY2014Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	2770000
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1803000
CY2014Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	436000
CY2014Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	41003000
CY2014Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2000
CY2014Q3	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	11123000
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1594000
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30699000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	33573000
CY2014Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	101168000
CY2014Q3	enta	Accrued Third Party License Fee Current AccruedThirdPartyLicenseFeeCurrent	240000
CY2014Q3	enta	Accrued Preclinical And Clinical Expenses Current AccruedPreclinicalAndClinicalExpensesCurrent	493000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.59
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18707934	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	24.22
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	794816	shares
CY2015Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	185614	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18916750	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.17
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1566662	shares
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1958000
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	228001000
CY2015Q2	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	265000
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	6494000
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	345000
CY2015Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	98000
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	15023000
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1165000
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	228282000
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2117000
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	538000
CY2015Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	733000
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	382000
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	372000
CY2015Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2229000
CY2015Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	68000
CY2015Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1642000
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1614000
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3469000
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	168000
CY2015Q2	us-gaap	Liabilities Liabilities	9492000
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	237774000
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	189000
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2062000
CY2015Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	608000
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7312000
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-74000
CY2015Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1457000
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2010000
CY2015Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	175000
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	25288000
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	4287000
CY2015Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	192099000
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	19557000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	32250000
CY2015Q2	us-gaap	Assets Assets	237774000
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	124000
CY2015Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	208571000
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11724000
CY2015Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	1376000
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2582000
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	608000
CY2015Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	57657000
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2000
CY2015Q2	us-gaap	Assets Current AssetsCurrent	172640000
CY2015Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	134442000
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	1757000
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3497000
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19844000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	37517000
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	192155000
CY2015Q2	enta	Accrued Third Party License Fee Current AccruedThirdPartyLicenseFeeCurrent	198000
CY2015Q2	enta	Accrued Preclinical And Clinical Expenses Current AccruedPreclinicalAndClinicalExpensesCurrent	656000
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	0	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.06
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	25111000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y22D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0189	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	892537	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19168368	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18275831	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.16
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	543000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	105000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	85750000
	us-gaap	Net Income Loss NetIncomeLoss	39480000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2000
	us-gaap	Revenues Revenues	45104000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-161000
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1475000
	us-gaap	Operating Income Loss OperatingIncomeLoss	24311000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	47000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1636000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-409000
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-268000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	39478000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	24358000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	329000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15122000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	7413000
	us-gaap	Share Based Compensation ShareBasedCompensation	1887000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	46000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-10000
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	711000
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	20793000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	17515000
	us-gaap	Interest Expense InterestExpense	14000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8716000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1120000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13538000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-200000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1015000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7255000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	105000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	70164000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-190000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	242000
	us-gaap	Paid In Kind Interest PaidInKindInterest	14000
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-15228000
	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	1824000
	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.80
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	79048000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	39485	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y11D
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0185	pure
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001177648
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10000000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M12D
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	32.47
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.74	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	42.33
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	617025	shares
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Entity Registrant Name EntityRegistrantName	ENANTA PHARMACEUTICALS INC
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19276767	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.88
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18659742	shares
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	us-gaap	Operating Income Loss OperatingIncomeLoss	120474000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	798000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1651000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	513355	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y4M24D
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	756000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	1817000
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, fair value of investments, valuation of warrants, Series 1 nonconvertible preferred stock and stock-based awards; the useful lives of property and equipment; and the accounting for income taxes, including uncertain tax positions. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</p> </div>
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	113360	shares
	dei	Trading Symbol TradingSymbol	ENTA
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.92
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	155583000
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	600000
	us-gaap	Net Income Loss NetIncomeLoss	73180000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	26000
	us-gaap	Revenues Revenues	146464000
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	4000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1108000
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-1394000
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	21000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	172000
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	144000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	26000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	73206000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	121272000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	660000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	39566000
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	175000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	48092000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2210000
	us-gaap	Share Based Compensation ShareBasedCompensation	4041000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	134000
	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-9277000
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	821000
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	25990000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10855000
	us-gaap	Interest Expense InterestExpense	6000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-92284000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2381000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16140000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	391000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	564000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9850000
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	2229000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	1817000
	us-gaap	Maintenance Costs MaintenanceCosts	105000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	18000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	62017000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-332000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	435000
	us-gaap	Paid In Kind Interest PaidInKindInterest	6000
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	11076000
	enta	Onetime License Costs OnetimeLicenseCosts	50000
	enta	Office Leases Expire OfficeLeasesExpire	September 2022
	enta	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	5000000
	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	2063000
	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.61
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0193	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.76	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	674437	shares
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-428000
CY2015Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1584000
CY2015Q2	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	726000
CY2015Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	341000
CY2015Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9896000
CY2015Q2	us-gaap	Interest Expense InterestExpense	2000
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6253000
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3643000
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19203270	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18528833	shares
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.70
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	50053000
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-65000
CY2014Q2	us-gaap	Revenues Revenues	42051000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	34895000
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	36000
CY2014Q2	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-65000
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-65000
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	49988000
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	34931000
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	106000
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15122000
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	776000
CY2014Q2	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	15228000
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	237000
CY2014Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	7156000
CY2014Q2	us-gaap	Interest Expense InterestExpense	5000
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4553000
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2603000
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2014Q2	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0184	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.70	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	580862	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19277966	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18697104	shares
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	2418000
CY2015Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-57000
CY2015Q2	us-gaap	Revenues Revenues	11599000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1703000
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	287000
CY2015Q2	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-15000
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-57000
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2361000
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1990000
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	304000
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	40000
CY2015Q2	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0

Files In Submission

Name	View Source	Status
0001193125-15-284854-index-headers.html	Edgar Link	pending
0001193125-15-284854-index.html	Edgar Link	pending
0001193125-15-284854.txt	Edgar Link	pending
0001193125-15-284854-xbrl.zip	Edgar Link	pending
d16402d10q.htm	Edgar Link	pending
d16402dex101.htm	Edgar Link	pending
d16402dex102.htm	Edgar Link	pending
d16402dex311.htm	Edgar Link	pending
d16402dex312.htm	Edgar Link	pending
d16402dex321.htm	Edgar Link	pending
enta-20150630.xml	Edgar Link	completed
enta-20150630.xsd	Edgar Link	pending
enta-20150630_cal.xml	Edgar Link	unprocessable
enta-20150630_def.xml	Edgar Link	unprocessable
enta-20150630_lab.xml	Edgar Link	unprocessable
enta-20150630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g16402g91a63.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

2015 Q3 Form 10-Q Financial Statement

#000119312515284854 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA ENANTA PHARMACEUTICALS INC Stock $enta

2015 Q3 Form 10-Q Financial Statement

#000119312515284854 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta